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1. INTRODUCTION 
Metabolic syndrome is composed of a constellation of disorders like 
hypertension, dyslipidaemia, visceral obesity and hyperglycemia. The occurrence of 
these disorders together substantially increases the risk of cardiovascular diseases. In 
both developing as well as developed countries the epidemic of obesity and diabetes 
mellitus is in a ever increasing trend hence increasing the prevalence of metabolic 
syndrome world wide.
4 
Metabolic syndrome is a pro inflammatory condition. The risk of 
cardiovascular diseases in people with metabolic can be predicted by measurement of 
markers of inflammation like high sensitive C reactive protein. Several studies have 
shown that several components of metabolic syndrome are associated with CRP. The 
elevated CRP levels are caused due to the production of cytokines by adipocytes. 
Several cytokines are secreted by the adipose tissue among which is interleukin 6. 
Interleukin 6 causes upregulation of CRP production by the liver. Thus additional 
information about prognosis of cardiovascular risk in metabolic syndrome patients can 
be obtained by measuring the CRP levels.
7
 From India very little has been 
documented about this topic. The objective of the present study is to find the 
association between hs- CRP and components of metabolic syndrome.
4 
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2. REVIEW OF LITERATURE 
METABOLIC SYNDROME 
Metabolic syndrome which is also known as syndrome x or insulin resistance 
syndrome is constituted by a series of metabolic abnormalities which result in 
enhanced risk to diabetes, cardiovascular and cerebrovascular diseases. It was the 
World Health Organisation which  first formulated the original criteria for metabolic 
syndrome in the year 1988. However since then the criteria has undergone continuous 
evolution because of growing analysis, research and clinical evidence by variety of 
professional organisations and conferences. The important features that make up the 
metabolic syndrome consists of diabetes mellitus, central obesity, hypertension, 
hypertriglyceridemia, low high density lipoprotein-HDL
1 
The metabolic syndrome is defined by the  Current ATP III criteria as the 
presence of any three of the following five characteristics 
 Abdominal obesity, defined as circumference of  waist in men greater than 102 
cm  and in women greater than 88 cm  
 Serum triglycerides  greater than150 mg/dL  or  on treatment with drugs  for 
elevated triglycerides 
 Serum HDL cholesterol lesser than 40 mg/dL in men and lesser than 50 mg/dL 
in women or on  treatment with drugs for low HDL-C 
 Blood pressure greater than130/85 mmHg or on treatment with drugs for 
elevated BP 
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 Fasting plasma glucose (FPG) greater than 100 mg/dL  or on treatment with 
drugs for elevated blood glucose
1
 
Epidemiology 
The prevalence of metabolic syndrome around the world in general increased 
with age. More than about 40 % of middle aged people are affected with metabolic 
syndrome in developed countries. With increased growth and development, there is a 
rising rates of obesity even among developing countries which would increase the 
prevalence to alarming proportions even in developing countries. Moreover with 
increasing prevalence of obesity even among children metabolic syndrome might 
occur in a younger age in the future
6 
RISK FACTORS  
Overweight/Obesity 
Even though the term metabolic syndrome came into description only in the 
early part of twentieth century, the epidemic of obesity around the world has been a 
important force far earlier than the recent recognition of metabolic syndrome. The 
most important feature of this syndrome is Central Adiposity. This shows that there is 
a strong association between increasing obesity and waist circumference with 
development of metabolic syndrome. The major risk factor for development of 
metabolic syndrome is increased body weight. In NHANES III,  5  % of the people 
who had normal weight had metabolic syndrome, 22 % of the people who had 
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overweight had metabolic syndrome, and 60 % of the people who were obese had 
metabolic syndrome. 
In Framingham Heart Study cohort , it was found that with an increase in 
weight of more than 2.25 kg or more in people who were above 16 years it was found 
out that there was a increased chance of 21 to 45 % of developing metabolic 
syndrome. If we use a large waist circumference alone as a criteria it identifies about 
46 % of the people who will eventually end up having metabolic syndrome within 5 
years time. 
With increasing standard of living in our country , there is a alarming increase 
in the proportion of people who are becoming obese and this leads to even higher 
chance of metabolic syndrome in future. This shows the importance of increasing the 
physical activity among people and take measures actively to reduce obesity in order 
to reduce the prevalence of metabolic syndrome and its complications.
1 
Sedentary Lifestyle 
People who have prolonged physical inactivity are more prone to 
cardiovascular diseases and the mortality that arises from it. Several components 
which constitute the metabolic syndrome are associated with sedentary lifestyle. 
Sedentary life style increases adipose tissue in our body particularly the central 
adipose tissue, reduces the levels of HDL cholesterol and increases the level of 
triglycerides. It is also associated with increased blood pressure and elevated levels of 
blood glucose in those with genetic predisposition. A study revealed that in those 
people who did sedentary work like watching television or computer for more than 4 
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hours daily have twice the risk of developing metabolic syndrome than those who 
spent less than one hour in these sedentary activities.
27 
Aging 
As the age increases the prevalence of metabolic syndrome increases in most of 
the population around the world. A study conduction in united states revealed that 
about more than 44 % of the population over 50 years are affected with metabolic 
syndrome there. Moreover it was found out that the prevalence of metabolic syndrome 
was more in females than in males.
42
   
Diabetes Mellitus 
Diabetes mellitus is a chronic disease due to derangement in glucose 
metabolism in our body. A array of dysfuncitons constitute diabetes mellitus type 2. 
These include elevated glucose levels which occurs due to a combination of 
inadequate insulin secretion, increased resistance to the action of insulin, and 
excessive glucagon secretion.
32
 Most patients are asymptomatic in the  beginning. The 
classical symptoms of diabetes mellitus is polydipsia, polyuria, polyphagia and weight 
loss. Other associated symptoms include blurring of vision, increased tendency of 
infection. The ADA criteria for diagnosis of diabetes include fasting plasma glucose 
value of greater than 126 mg/l, a 2 hour plasma glucose level following meals of more 
than 200mg/l, a random plasma glucose value of greater than 200mg/ml. The 
microvascular complication of diabetes include neuropathy, nephropathy and 
retinopathy. The macrovascular complications of diabetes is due to the atherosclerosis 
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of large vessels which can lead to myocardial infarctions, stroke and peripheral 
vascular diseases. 
Screening for complication of diabetes include fundus examination, foot 
examination, urine for microalbuminuria and proteinuria and measurement of serum 
creatinine and lipid profile. 
International diabetes foundation as well as NCEP have diabetes mellitus as 
part of their definition for metabolic syndrome. Studies have shown that metabolic 
syndrome is present in about three fourth of patients with impaired glucose tolerance 
and type 2 diabetes. A higher risk of cardiovascular risk is present in metabolic 
syndrome patients when compared to those having diabetes or IGT alone without 
having metabolic syndrome.
6 
Coronary Heart Disease 
In those patients who have coronary heart disease the approximate prevalence 
of metabolic syndrome is 50 %. In those patients who have premature coronary  heart 
disease the prevalence is about 37 %. And this prevalence has been found to be more 
in women and this prevalence has been found to increase  with age. This prevalence 
can be reduced by incorporating changes in the lifestyle of people like advising them 
to take proper food with nutritive value, increase in the duration of physical activity 
undertaken in a day, taking steps to reduce weight and in some exceptional cases 
taking drugs. Thus with the help of these steps and appropriate cardiac rehabilitation 
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the occurrence of metabolic syndrome and cardiac morbidity and mortality associated 
with it can be reduced.
1 
Lipodystrophy 
Metabolic syndrome is associated with several lipodystrophic disorders which 
include both genetic and acquired. The genetic conditions include Berardinelli-Seip 
congenital lipodystrophy and Dunnigan familial partial lipodystrophy. The acquired 
conditions include HIV related lipodystrophy.
27
 Lipodystrophy leads to severe insulin 
resistance which in turn leads to several components of metabolic syndrome 
Family history 
When one of the parent has metabolic syndrome the likelihood of offspring 
also developing metabolic syndrome is increased.   
Other factors — 
Women who have attained their menopause, who smoke, who belong to low 
household income, who take in high quantities of carbohydrates , who do not consume 
alcohol and those people who consume large quantities of soft drinks are found to be 
associated with increased risk of developing metabolic syndrome in several studies.
12
 
People who take atypical antipsychotic medications especially clozapine are 
associated with significantly higher risk of developing metabolic syndrome.
16
 A 
strong independent predictor for developing metabolic syndrome in both men and 
women is poor cardiorespiratory fitness.
34
 Genetic factors account for as much as 50 
percent of variation in the traits of metabolic syndrome in offspring.
35 
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PATHOPHYSIOLOGY OF THE METABOLIC SYNDROME 
The expanded mass of adipose tissue releases free fatty acids in large quantities 
into the blood stream. These free fatty acids are transported to the liver were they are 
processed and are used to produce increased quantities of triglycerides and glucose 
and increased secretion of VLDL- very low density lipoproteins. This is associated 
with derangements in lipid with reduction in the good cholesterol which is HDL with 
increase in bad cholesterol which is LDL. 
Free fatty acids inhibit the insulin mediated glucose uptake in the muscles 
reducing the sensitivity of insulin in the muscles. There is also associated increase in 
the accumulation of lipid in the triglycerides with reduced partitioning of glucose to 
glycogen. Hyperinsulinemia occurs as a result of increased stimulation of the pancreas 
by the elevated circulating levels of glucose and free fatty acids resulting in increased 
insulin secretion. This hyperinsulinemia  leads to increased sodium absorption. This 
increased sodium leads to increased activation of the sympathetic nervous system. 
Both these contribute to development of hypertension. 
There is a proinflammatory state which superimposes and also contributes to 
the insulin resistance produced by increased free fatty acids. The adipocytes and 
monocyte derived macrophages secrete increased quantities of tumour necrosis factor 
and interleukin 6. These inflammatory cytokines increase the insulin resistance and 
result in increased lipolysis of the triglycerides in the adipose tissue converting them 
into free fatty acids and thus releasing them in increased quantities into circulation.  
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These cytokines also increase the glucose production in the liver, enhance the 
liver production of  VLDL and increase the resistance to insulin in the muscles. 
Cytokines and free fatty acids result in a prothrombotic state by enhancing the 
fibrinogen production by the liver and enhancing the production of plasminogen 
activator inhibitor by the adipocytes. 
There is increased levels of C- reactive protein due to elevated circulating 
levels of the inflammatory cytokines which stimulate the liver to produce CRP. 
Metabolic syndrome is also associated with reduced insulin sensitizing cytokine 
adiponectin and decreased release of anti inflammatory cytokines.
1 
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DIABETES MELLITUS 
Insulin Resistance  
Insulin resistance is the widely accepted hypothesis to describe the patho 
physiology involved in metabolic syndrome.
43
 This is due to a incompletely 
understood dysfunction in the action of insulin. When a person develops insulin 
resistance there is first postprandial hyperinsulinemia then there is fasting 
hyperinsulinemia and finally there is hypergylcemia. 
Overabundance of free fatty acids in circulation is a important contributor to 
the development of insulin resistance in our body. The lipolytic enzyme lipase is 
responsible for the majority of plasma free fatty acids which are bound to albumin.
25
 
The lipase enzyme acts on the adipose tissue triglyceride stores releasing the free fatty 
acids. Lipoprotein lipase  enzyme causes lipolysis of triglyceride rich lipoproteins 
releasing fatty acids in blood. Insulin causes both stimulation of lipoprotein lipase as 
well as antilipolysis in the adipose tissue.
8
 The most sensitive pathway in the action of 
insulin is the inhibition of lipolysis in the adipose tissue. So when resistance to the 
action of insulin occurs there is increased lipolysis of adipose tissue  releasing free 
fatty acid in bloodstream which further decreases the antilipolytic effect of insulin. 
This increased fatty acids enhance the availability of substrate and modifies 
downstream signalling creating insulin resistance. The elevated fatty acids inhibit the 
insulin mediated glucose uptake and cause triglycerides to accumulate in both cardiac 
and skeletal muscle. This is associated with accumulation of triglycerides and 
increased production of glucose in liver. A unifying theory for both predisposition for 
12 
 
metabolic syndrome as well as for aging is provided by oxidative stress hypothesis. 
Studies showed that there is a defect in oxidative phosphorylation in mitochondria in 
insulin resistant obese  individuals, in elderly, in type 2 diabetic patients and their 
offsprings. This defect leads to lipid accumulation in the muscle associated with 
insulin resistance. This defective insulin action causes reduced uptake and metabolism 
of glucose in the tissues which are sensitive to insulin like adipose tissue and muscles. 
It also causes decreased suppression of production of glucose by the liver and kidney. 
Studies conducted in rodents, nonhuman primates and in humans support the 
relationship between impaired glucose tolerance/impaired fasting glucose and insulin 
resistance.
52
 In order to maintain euglycemia the body modifies the level and rate of 
insulin secretion and clearance to compensate for the defect in the action of insulin. 
However ultimately when this compensatory mechanism fails which occurs mainly 
because of decreased insulin secretion there is progression from IFG/IGT to frank 
diabetes. 
1 
Increased Waist Circumference 
One of the important component of the diagnostic criteria which is frequently 
applied to diagnose patients with metabolic syndrome is waist circumference. But just 
by measuring the waist circumference we cannot reliably distinguish between increase 
in visceral fat and subcutaneous adipose tissue. CT or MRI scan is required in order to 
make this distinction. When there is increase in adipose tissue present in the viscera, 
the free fatty acids that are derived from adipose tissue are directed to the liver. 
However when there is increase in subcutaneous fat in the abdomen, the products of 
13 
 
lipolysis are released into the systemic circulation and these avoid the more direct 
effects on the liver metabolism.
47
 In Asians and in Asian Indians the relative increase 
in visceral fat when compared to subcutaneous fat along with increase in waist 
circumference when compared with African American men inn whom subcutaneous 
fat predominates is responsible for the increased incidence of metabolic syndrome 
among Asian and Asian Indians.
8 
Hence visceral fat can be used as a marker for but 
not source of increased levels of post prandial free fatty acids in obese peoples.
11 
Dyslipidemia 
The influx of free fatty acids into the liver causes increased production of apo 
B containing triglyceride rich very low density lipoproteins.
16
 This is done by a 
complex mechanism but however we can use HYPERTRIGLYCERIDEMIA as an 
excellent marker for insulin resistant conditions. 
The second major derangement in lipid profile in people with metabolic 
syndrome is reduction in the levels of HDL cholesterol. The changes which occur in 
the metabolism and composition of  HDL is responsible for this reduction. Reduction 
in the levels of cholesteryl ester in the lipoprotein core along with reduction in 
cholesteryl ester transfer protein mediated alterations in triglyceride in the presence of 
hypertriglyceridemia is responsible for decreasing the cholesterol amount in HDL 
making the particle small and dense.
8 
This changes in composition of  lipoproteins also result in increased rate of 
clearance of HDL from the circulation.
24
 The relationship between insulin resistance 
14 
 
and changes in HDL are probably indirect and these occur in coherent with changes in 
metabolism of triglyceride rich lipoprotein.
1 
In addition to these changes there is modification in the composition of low 
density lipoproteins too. Small dense LDLs almost always predominate in the blood 
when fasting serum triglycerides are more than 180 mg/dl. These small dense LDLs 
are found out to be highly atherogenic. These causes toxic damages to the 
endothelium of blood vessel and these pass through the basement membrane of the 
endothelium and adhere to the glycosaminoglycans. These also get easily oxidised and 
they are bound selectively to scavenger receptors in the monocyte derived 
macrophages. There is increased cholesterol content in both VLDL1 and VLDL2 
subfractions in people with hypertriglyceridemia and elevated levels of small dense 
LDL particles. The atherogenic risk in patients with metabolic syndrome might be 
contributed by these relatively cholesterol rich VLDL particles.
1 
Glucose Intolerance 
There is impaired suppression of the production of glucose in the liver and in 
the kidney due to defective action in insulin. The defects in insulin action also leads to 
decreased uptake of glucose and reduction in metabolism of glucose in the adipose 
tissues and muscles which are the insulin sensitive tissues. In order to compensate for 
the defects in the action of insulin either insulin clearance or the rate of secretion of 
insulin has to be modified if the euglycemic levels are to be sustained.
24
 Eventually 
there is failure of this compensatory mechanism which mostly results from reduction 
in insulin secretion leading to progression of IGT/IFG to frank diabetes.
1 
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Hypertension 
There is a well established relationship between hypertension and insulin 
resistance. Under normal physiologic conditions paradoxically insulin acts like a 
vasodilator with reabosoption of sodium in the kidney as its secondary effect. But 
when there is resistance to insulin there is loss of the vasodilatory action of insulin. 
However the action of insulin on the kidney causing sodium reabsorption is preserved. 
The activity of the sympathetic nervous system is also increased by insulin , an action 
which inspite of the presence of insulin resistance is preserved. There is impairment in 
the pathway in phosphatidylinositol 3 kinase signalling in insulin resistance. This 
leads to imbalance between the endothelin 1 secretion and nitric oxide production in 
the endothelium. Inspite of all this insulin resistance leads to only moderate increase 
in the prevalence of hypertension in metabolic syndrome.
1 
Proinflammatory Cytokines 
There is overproduction of proinflammatory cytokines by the expanded mass of 
adipose tissue. The proinflammatory cytokines include interleukin IL-1, IL-18, IL-6, 
CRP- c reactive protein, restin and tumour necrosis factor(TNF)
39
. The primary source 
of these pro inflammatory cytokines both in the systemic circulation as well as locally 
is the macrophages derived from adipose tissue. However it is unclear as to how much 
the paracrine and endocrine effects of these cytokines lead to insulin resistance.
1 
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Adiponectin 
Adipocytes produce an anti inflammatory cytokine exclusively called 
adiponectin. This adiponectin increases the sensitivity of insulin and it inhibits the 
inflammatory process in several steps. Adiponectin inhibits the gluconeogenic 
enzymes and thus reduces the rate of production of glucose in the liver.
8
 Adiponectin 
enhances the transport of glucose in the muscles and increases the oxidation of fatty 
acids partly because of activation of adenosine monophosphate kinase. In metabolic 
syndrome this adiponectin is reduced. This increases the inflammation associated with 
metabolic syndrome
1
.
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ASSOCIATED DISEASES 
Cardiovascular Disease 
The patients who have metabolic syndrome have a increased relative risk of 
about two to three fold for developing new onset cardiovascular diseases. According 
to Framingham offspring study which is a 8 year follow up study the attributable risk 
for metabolic syndrome to develop in men is about 34% and in women is about 18 %. 
This study also showed the increased risk of developing ischemic stroke in patients 
who had both metabolic syndrome and diabetes than diabetes alone especially among 
females. There is increased risk of peripheral vascular diseases also among metabolic 
syndrome patients.
1 
Type 2 Diabetes 
The overall risk of developing diabetes is increased three to five fold  among 
metabolic syndrome patients. The Framingham offspring study showed that the risk of 
developing diabetes in  metabolic syndrome patients during its 8 year follow up period 
was 62 percent in men and about 47 percent in women.
1
  
Other Associated Conditions 
Metabolic syndrome is associated with other metabolic alterations which 
accompanies insulin resistance in addition to specific features associated with it. 
These include increase in  CRP,  uric acid, prothrombotic factors like fibrinogen and  
plasminogen activator inhibitor 1, asymmetric dimethylarginine, homocysteine, 
proinflammatory cytokines, obstructive sleep apnea (OSA), microalbuminuria, in 
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apoB and apoC-III, white blood cell count, nonalcoholic fatty liver disease (NAFLD) 
and/or nonalcoholic steatohepatitis (NASH), polycystic ovarian disease (PCOS) and 
serum viscosity
8 
Nonalcoholic Fatty Liver Disease 
Both inflammation and triglyceride accumulation coexist in non-alcoholic fatty 
liver diseased. Studies show that 2-3% of the population in western countries and in 
united states suffer from non alcoholic fatty liver disease. Non alcoholic fatty liver 
disease has increasingly now become a very common cause of end stage liver 
cirrhosis and carcinoma of liver due to ever increasing prevalence of obesity and 
metabolic syndrome increases all over the world including developing nations like 
india.
45 
Hyperuricemia 
Defective insulin action on absorption of uric acid by the renal tubules leads to 
hyperuricemia. 
1 
Endothelial dysfunction 
Increase in asymmetric dimethylarginine which is a endogenous inhibitor of the 
enzyme nitric oxide synthase leads to damage and dysfunction of endothelium.
8 
Microalbuminuria 
Altered endothelial pathophysiology in persons with insulin resistant state 
cause microalbuminuria. 
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Polycystic Ovary Syndrome 
In persons with metabolic syndrome there is high association of 40 -50 %  for 
developing polycystic ovary syndrome. Studies show that there is two to four fold 
likelihood of developing PCOS in women with metabolic syndrome than in normal 
women.
1 
Obstructive Sleep Apnea 
The factors which are commonly associated with obstructive sleep apnea 
include increased circulating cytokines, IGT, insulin resistance, obesity and 
hypertension. These are the same conditions which are associated with metabolic 
syndrome and so its not surprising to find a high association between metabolic 
syndrome and OSA. Studies have shown that when we compare insulin resistance bio 
markers between weight matched controls and people with OSA, insulin resistance is 
more severe in patients with OSA. It has been shown that CPAP-continuous positive 
airway pressure as treatment improves the sensitivity to insulin in metabolic syndrome 
patients.
1 
DIAGNOSIS 
Metabolic syndrome is diagnosed by a criteria given by several organisation 
using bedside tools and using lab investigation. All patients with OSA and PCOS 
should be evaluated for history if they have metabolic syndrome. Family history will 
help us estimating the risk of developing DM and CVD. Measurement of waist 
circumference and blood pressure will provide essential information for diagnosis.
1 
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Laboratory Tests 
Glucose and fasting lipids are necessary to diagnose if metabolic syndrome are 
present. The measurement of extra biomarkers has to be individualized. These include 
high sensitivity CRP, uric acid, fibrinogen, liver function test, urinary 
microalbuminuria and apoB .If OSA is suspected then the patient must be subjected to 
sleep study. If symptoms of PCOS are present based on clinical features and 
anovulation then testosterone, FSH and luteinizing hormone  should be measured.
1 
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THERAPY  
The recommendations of ATPIII in 2001 for patients having metabolic 
syndrome include two major therapeutic goals. Studies from National Institutes of 
Health, The Endocrine Society and American Heart Association have reinforced these 
goals. These include 
 The underlying cause of metabolic syndrome which is physical inactivity and 
obesity have should be treated first by increasing physical activity and 
intensifying steps to manage overweight.
1
 
 The cardiovascular risk factors should be treated if these risk factors persist 
despite of making lifestyle modifications
11
 
Lifestyle 
The major driving force behind metabolic syndrome is obesity. Thus the 
primary approach to treat this disorder is reduction of weight. When there is reduction 
in weight there is improvement in sensitivity to insulin and is accompanied by 
favourable changes in several metabolic syndrome components. For reduction in 
weight the general recommendations include a combination of restriction of calorie 
intake, taking appropriate balanced nutritional diet, avoiding junk food, increasing 
physical activity and modification of behaviour. Caloric restriction is the most 
important component for weight reduction. However for maintenance of the reduced 
weight the most important component is physical activity. Some studies show that 
when exercise is combined with caloric restriction there is increased loss of visceral 
22 
 
depot of fat. Long lasting behavioural changes are necessary to prevent regaining of 
weight in people who have successfully reduced their weight.
1 
Diet 
The following specific diet approaches have been recommended: 
 The Mediterranean diet- it consist of a diet high in vegetables, fruits, whole 
grains, nuts and olive oil with a low fat. Studies showed that subjects who were 
in this Mediterranean group had higher weight loss, improved lipid profiles, 
lower blood pressure, decreased resistance to insulin, less endothelial 
dysfunction and reduced levels of markers of inflammation.
50
 
 The DASH diet- it consist of a diet with limited daily sodium intake of 2400 
mg. this diet emphasised a higher diary intake of when compared to 
Mediterranean diet. This diet gave importance to healthy food choices resulting 
in improvements in lipid profile, reduction in diastolic blood pressure and 
fasting blood glucose even after causing reduction in weight.
9
 
The glycemic status and lipid abnormalities can be improved by taking foods 
with low glycemic index, by consuming increased amount of fruits and vegetables, by 
replacing refined grains with whole grains, stopping consumption of high glycemic 
beverages and taking high fiber foods.
52 
It is important to emphasize when we prescribe a weight loss diet that it takes 
long time to achieve a expanded fat mass. Hence we need not quickly do the 
corrections. When the carbohydrate rich diets are restricted there is initial rapid loss of 
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weight. But however the amount of weight loss after one year remain unchanged. So 
adherence to the diet is very important. In diets which contain high amounts of 
saturated fat with reduced carbohydrates there is a increased risk of developing 
cardiovascular diseases. Hence a good quality diet must be encompass vegetables, 
fruits, whole grains, fish, lean poultry and the person should be encouraged to take 
such a diet to provide maximum overall health benefit.
1 
Physical Activity 
When physical activity is recommended for metabolic syndrome patients it is 
important to make sure that the increased activity does not cause risk.
21
 
Cardiovascular evaluation must be done for high risk patients before they are started 
on an exercise program. A gradual level of increase in physical activity should be 
encouraged since it would reduce the injury risk and enhance adherence. A 60 to 90 
min or daily physical activity is required to achieve modest weight loss. If an obese 
person is not able to achieve this level of physical activity, at least a 30 min moderate 
level of physical activity daily will result in tremendous benefit to them. Formal 
exercise such as jogging, swimming and tennis alone do not define physical activity. 
Routine house hold activities like walking, house cleaning , gardening etc.. which 
require moderate physical activity can be included.
1 
Obesity 
However for a few patients life style interventions alone will not suffice. The 
two major classes for weight loss reducing drugs include appetite suppressants and 
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absorption inhibitors. US FDA approved appetite suppressants include sibutramine 
and phentermine. Orlistat reduces the incidence in type 2 DM and inhibits fat 
absorption by 30 %. 
For patients who have a body mass index of greater than 40 kg/m
2 
or greater 
than 35 kg/m
2 
with co morbidities bariatric surgery is an option. There is dramatic 
reduction in weight and improvement in features of metabolic syndrome following 
bariatric surgery.
35 
LDL Cholesterol 
LDL cholesterol should be reduced to <100 mg/dl for patients with metabolic 
syndrome and diabetes. The 10 year risk of cardiovascular diseases in in patients with 
metabolic syndrome without diabetes according to the Framingham risk score exceeds 
greater 20 %. In these subjects the LDL target is less than 100 mg/dl. For those in 
whom the Framingham risk score is less than 20 % the targeted LDL cholesterol goal 
is < 130 mg/dl.
26
  
Lipid control 
The diet should be restricted in trans fats, saturated fats and cholesterol. 
Pharmacologic intervention is needed if the level of LDL cholesterol remains above 
the goal. HMG CoA reductase inhibitors- Statins are the first choice of drugs which 
lower the LDL cholesterol by 20 to 60 %. However whenever we double the dose of 
statins there is only additional 6% lowering of LDL cholesterol. Myopathy and 
elevation in hepatic transaminases are rare side effects with statin therapy. The second 
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choice of drug is ezetimibe which is a cholesterol absorption inhibitor. Colestipol and 
cholestyramine which are bile acid sequestrants are more effective than ezetimibe 
however these increase the levels of triglycerides and hence should be used in caution 
with metabolic syndrome patients. When the fasting triglycerides are more than 200 
mg/dl bile sequestrants should not be administered. The side effects are bloating, 
constipation, difficult palatability, belching and anal irritation. Nicotinic acid increases 
the level of HDL however the LDL lowering capabilities is only modest. When both 
LDL cholesterol and triglycerides are elevated fibrates are the best choice of drugs to 
lower LDL cholesterol. Fenofibrate is a better drug and more effective than 
gemfibrozil in this group.
1 
Triglycerides 
The focus of NCEP ATP III has been more on non HDL cholesterol rather than 
triglycerides. However the recommended value of fasting triglyceride level is less than 
150 mg/dl. The response of fasting triglycerides is directly related to the amount of 
loss of weight achieved. In order to lower the level of fasting triglycerides a weight 
reduction of greater than 10% is required 
The drug of choice to reduce the level of fasting triglyceride level is fibrates 
like gemfibrozil and febofibrate. These typically reduce the levels by 35- 50%. 
However when these drugs are administered with other drugs metabolised by the 3A4 
cytochrome P450 system including some statins then the chances of developing 
myopathy is greatly increased. Fenofibrate is a more preferred drug when compared to 
statins in these settings. Even though several clinical trials have been conducted there 
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is no clear cut evidence to support the CVD risk lowering effect by using fibrates to 
reduce the triglyceride level.
1 
Statins, high doses of omega 3 fatty acids and nicotinic acid are other drugs 
which lower triglyceride level. When statin is used, the more potent ones like 
simvastatin, rosuvastatin and atorvastatin should be given in moderate doses while the 
less potent ones like lovastatin, fluvastatin and pravastatin should be given in high 
doses. Nicotinic acid has a dose related and less effect than fibrates on fasting 
triglyceride levels. Omega 3 fatty acid preparations contain high doses of 
eicosapentaenoic acid and docosahexaenoic acid.
38
 These lower the fasting 
triglyceride levels by 40%. 
HDL Cholesterol 
Reduction of weight increases the level of  HDL. There are only a very few 
lipid modifying compounds which are capable of increasing HDL cholesterol values. 
Nicotinic acid is the only drug which is currently available which has a predictable 
HDL cholesterol raising properties. There is dose related response and it can cause 
about 30 % increase in HDL values above baseline. The drugs which have a modest 
action on HDL levels are statins, fibrates and bile acid sequestants. Omega 3 fatty 
acids and ezetimibe have no effect on HDL cholesterol levels. However there is only 
limited evidence at present that raising HDL cholesterol independent of lowering LDL 
cholesterol has a reducing effect on cardiovascular diseases in patients with metabolic 
syndrome.
1 
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Blood Pressure 
A well established relationship is the one between blood pressure and all cause 
mortality rate.
11
 In those patients who have metabolic syndrome without diabetes 
mellitus angiotensin converting enzyme or angiotensin II receptor blocker should be 
the first choice to reduce hypertension since they reduce the incidence of type II DM 
among metabolic syndrome.
14
 The  diet for these patients must have low sodium, high 
quantities of fruits and vegetables and low dairy fat products. Good blood pressure 
control can be maintained by home monitoring of blood pressure.
1 
Impaired Fasting Glucose 
Prevention of type 2 diabetes  
Studies have shown that by doing lifestyle modifications we can substantially 
reduce the risk of developing type two diabetes mellitus and the chances of 
developing cardiovascular diseases. In diabetes prevention program about 3234 obese 
subjects with impaired glucose tolerance or impaired fasting glucose were put into 
three groups. One group with intensive lifestyle changes through exercise and low fat 
diet, second group with metformin with information about exercise and diet and third 
group on placebo with information on exercise and diet. After three years of follow up 
it was found out that less number of patients in the intensive lifestyle group developed 
diabetes.
9 
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Oral hypoglycemic agents  
Within the oral hupoglycemic agents which are used to treat type 2 diabetes 
mellitus it was found out that metformin and thiazolidinediones like rosiglitazone and 
pioglitazone enhance the sensitivity to insulin in part and hence have better glucose 
tolerance.
12
 The development of diabetes in patients with impaired glucose tolerance 
can be delayed or prevented by using metformin. According to Diabetes Prevention 
Program trial the group of people on metformin were associated with 31% reduction 
in risk of developing diabetes when compared to those on placebo. But it was found 
out that metformin was inferior to lifestyle modification in preventing diabetes. Both 
intensive lifestyle intervention and metformin therapy are good in preventing the 
occurrence of metabolic syndrome in those who doesn’t have the syndrome in 
baseline. 
Diabetes related end points can also be reduced by the use of metformin. 
According to the United Kingdom Prospective Diabetes Study (UKPDS) 
51
it has been 
found out that metformin reduces all the diabetes related end point such as angina, 
myocardial infarction, stroke, heart failure, renal failure, retinopathy, monocular 
blindness, cataract, hypo or hyperglycemia and sudden death. 
14 
The current recommendations for people suffering from impaired glucose 
tolerance and impaired fasting glucose is to reduce the weight loss to about 5 to 10 % 
of the base line and take a diet with low levels of trans fats, saturated fats, simple 
sugars, cholesterol, increased intake of fruits, vegetables, whole grains and do 
moderate intense physical activity for atleast 30 minutes per day. We need not 
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routinely give drugs to prevent diabetes. However in certain patients with IGT and 
IFG we can consider giving metformin. 
In those patients who have both type 2 diabetes mellitus and metabolic 
syndrome aggressive glycemic control will result in reducing the levels of 
triglycerides and increasing HDL levels. The transition from IFG to frank type 2 
diabetes can be reduced by undergoing lifestyle intervention like dietary fat reduction, 
weight reduction and increased physical activity. Metformin was also found to retard 
the progression to diabetes however the action is less efficient than what is seen with 
lifestyle modification.
1 
Insulin Resistance 
Biguanides and thiazolidinediones are the drugs which increase the sensitivity 
to insulin. The prevalence of metabolic syndrome can be reduced by using these drugs 
because insulin resistance is the major pathophysiologic mechanism for development 
of metabolic syndrome. Both these drugs suppress the endogenous glucose production 
and increase the action of insulin in the liver. Insulin mediated uptake of glucose in 
the adipose tissue and the muscle is improved by thiazolidinediones.
25
 These drugs 
decrease the levels of small dense LDL and reduce the inflammatory markers. Both 
patients with PCOS and NAFLD are found to benefit from these drugs
1
. 
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CRP- C REACTIVE PROTIEN 
An important component of our immune system is CRP. About approximately 
70 years ago CRP was first discovered by scientist when they were exploring the 
human inflammatory response. It has been only recently uncovered about the role of 
CRP in heart diseases. 
CRP is being made in everyone but the level varies from person to person 
depending upon a wide range of factors including  lifestyle habits and genetics. It has 
been found that on a average the CRP levels are higher in those individuals who are 
over weight, who fail to exercise, who smoke , who have high blood pressure that 
those who are athletic thin individuals. It has been found that about half of the 
variation in CRP levels have been inherited and are due to genetic reasons. However 
this is not a surprising fact since the fundamental role of CRP is inflammation and 
inflammation is a very important proves in healing of wounds, in protecting us against 
virus and bacteria and it is a component of various processes which are critical for 
survival. 
It has been found out by studies that too much inflammation in detrimental in 
few circumstances especially in the blood vessels which are responsible for carrying 
nutrients and oxygen to all the tissues in our body. Several research shows us that 
atherosclerosis which is a process that leads to accumulation of cholesterol in the 
arteries are due to inflammation of the blood vessels just like how arthritis is a 
inflammatory disorder of the joints and bones. 
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It has been found out that among those individuals who have a future high risk 
of developing heart diseases there has been found to be elevation of markers of 
inflammatory process in our blood. Inflammation plays a very huge role in all the 
steps of heart diseases. Inflammation is found to be involved in early initiation of 
atherosclerotic plaques in the vessel walls. Inflammation is also responsible for the 
acute rupturing of the plaques that causes heart attacks and in sudden death as well. 
CRP serves as a easy and very stable biomarker to measure inflammation. 
It has been demonstrated in about a dozen major studies that in apparently 
healthy individuals baseline CRP values serve as a predictor for future risk of 
developing stroke, peripheral arterial disease,  myocardial infarction and sudden 
cardiac death. Several studies also reveal that the recurrence of coronary events 
among patients who already suffer from heart diseases is predicted by CRP levels and 
the CRP is also tightly connected with the prognosis of patients during the acute phase 
of heart attack. However the most important current use of CRP is in the field of 
primary prevention. It is used to detect high risk among those people who don’t still 
yet know they have a problem.
53 
HIGH SENSITIVE CRP 
There is two to three times higher risk in individuals who have high CRP levels 
than those who have low levels. It is important to do high sensitive CRP if it is used to 
assess the risk of cardiovascular diseases. Its important because older test for CRP 
don’t have the ability to measure levels in the range which detects cardiovascular risk. 
Older CRP test monitor only severe inflammatory conditions. Hs CRP is just a simple 
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inexpensive blood test. When blood cholesterol levels are checked, Hs CRP levels can 
be checked along with it to assess the overall risk .
53 
C reactive protein is a blood marker for inflammation. It has a role in several 
chronic diseases such as diabetes, heart disease and stroke. Several scientific studies 
have shown that C reactive protein is not only a risk factor for stroke and heart 
diseases but when the levels of C reactive protein are reduced then the persons risk for 
heart diseases is substantially lowered.
54
 Inflammation is thought to augument the 
deposition of fat and other materials in the lining of blood vessels and promote the 
build up of atherosclerotic plaques. Inflammation favours especially the built up of 
vulnerable plaques which are highly prone to break up and disseminate as clots which 
can block the vessels causing stroke and heart attack.
3 
Physicians health study revealed that over a 8 to 10 years follow up the men 
who had heart attacks and strokes had a higher level of CRP than those who didn’t 
have them. Those who had the highest CRP levels had two times more risk of stroke 
and three times more risk of myocardial infarction than those with lowest levels. 
According to a study report in DIABETES CARE journal in 2004 men with diabetes 
with highest quartile of CRP levels had nearly thrice cardiovascular events like heart 
attack , angioplasty, bypass surgery and stroke) than those with lowest quartile.
54 
The concept of CRP underwent a drastic change following the publication of 
two landmark studies in the January 6, 2005 issue of the of The New England Journal 
of Medicine. The studies are those published by Paul M. Ridker, MD, and colleagues 
at Brigham and Women’s Hospital and Harvard Medical School in Boston. These 
33 
 
studies studied the effect of high doses of statin drugs which decrease the levels of 
both cholesterol and CRP in patients who had severe heart ailment. It was found out 
that Lower the levels of CRP the lesser the heart attacks and deaths in subjects 
irrespective of their LDL cholesterol levels. Studies conducted at the Cleveland clinic 
in Ohio by Steven E Nissen MD and colleagues showed that people who take high 
dose statin therapy had slower progression to atherosclerosis when compared to those 
taking moderate doses. They also found out that those with lower CRP levels had 
slower progression irrespective of their cholesterol levels. It was found out that 
lowering CRP levels was as important as lowering cholesterol values in prevention of 
heart diseases.
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In development of diabetes too inflammation plays a important role. According 
to the cardiovascular health study it was found out that those people who had high 
level of CRP were twice as likely to develop diabetes than those who had low values. 
Thus many researchers postulate that inflammation might be the same underlying 
pathology for both diabetes and atherosclerosis explaining the reason why diabetes are 
more prone to develop atherosclerosis , heart attacks and stroke.
54 
   
According to the American Heart Association and the Centers for Disease 
Control and Prevention current guidelines, CRP testing is recommended for those 
with intermediate risk of heart attack- that is those people who have a 10 to 20 % risk 
of developing heart attack in the next 10 years.
30
 The risk factors for heart diseases are 
being order than 55 years for female, being older than 45 years for male, overweight , 
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having high blood pressure, smoking, having low HDL levels and high LDL levels, 
family history of diabetes , stroke and heart attacks.
54 
For those people who have elevated levels of CRP the steps to prevent heart 
diseases include losing weight, diet control, exercise, stopping smoking all of which 
lower the level of CRP. Statins which are usually used to lower the levels of 
cholesterol has been found to lower the CRP values. Moreover CRP levels tend to 
increase with increasing glycosylated haemoglobin levels. Hence CRP levels can be 
reduced if blood glucose levels are kept under control. 
Interpreting CRP results 
It is desirable to have CRP levels less than 1 mg/L and this reflects low overall 
risk of cardiovascular diseases. Those who have levels between 1 and 3 mg/L have 
moderate risk. And elevated risk of cardiovascular diseases has been found in patients 
who have CRP values in excess of 3 mg/L. 
53 
Who have to be tested for CRP? 
According to the American Heart Association and The Centers for Disease 
Control and Prevention, evaluation of CRP should be considered as a part of 
prediction of vascular risk in individuals especially those who have intermediate 
risk.
34
 To avoid unnecessary blood draws and to increase the risk of clinical practice 
many physicians add CRP testing to standard cholesterol evaluation. American heart 
association and CDC also endorse the evaluation of CRP in those who have history of 
heart attack and those who were have been admitted with acute coronary syndromes in 
hospital.
3 
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People in their mid-30s should be subjected to CRP evaluation. It was found out that 
CRP levels in your teens and 20s is predictive of CRP levels in the later part of ones 
life. The risk over next 30 to 40 years is predicted by elevated CRP levels. This gives 
us ample time to advocate for changes in lifestyle , diet , exercise and if needed to 
initiate pharmacological interventions to prevent first ever attack of stroke and heart 
attack. 
53 
DIABETES AND CRP 
Type 2 diabetes is a prothrombotic, pro atherosclerotic and pro inflammatory 
condition with high association for cardiovascular morbidity. CRP serves as a bio 
marker for low grade of inflammation in type 2 diabetes patients. The likelihood of 
developing cardiovascular events are elevated with increase in CRP levels in both 
diabetic and non diabetic populations. In healthy individuals the elevated level of CRP 
serves as a marker for developing diabetes. There is also evidence that CRP might be 
a active participant in atherogenesis besides its rode as a marker for cardiovascular 
diseases. 
49 
Human atherosclerotic plaques express CRP. The vascular cells and monocytes 
and macrophages are the source of CRP in the vessel wall. Within the atherosclerotic 
plaques activation of the main cell types causes release of CRP within the lesion 
contributing to the development and progression of atherosclerosis. Recent studies 
reveal that CRP production by the monocytes, macrophages, endothelial cells and 
smooth muscles are triggered by several metabolic and inflammatory factors 
associated with diabetes like adipokines, high glucose levels, free fatty acids and 
modified lipoproteins. Studies suggest that diabetic atherosclerotic plaques might have 
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higher levels of CRP concentration when compared to non diabetic ones. This might 
lead to accelerated development of vascular disease in type 2 diabetes patients. 
Studies have suggested that the development of macrovascular complications 
in diabetes is significantly increased with poor glycemic control. And studies have 
indicated that CRP is a important risk factor for cardiovascular diseases and with 
increasing value of HbA1c levels the CRP levels too increase. This shows that a 
association is present between systemic inflammation and glycemic control in people 
with established type 2 diabetes mellitus.
49 
Studies have shown that CRP levels have been found to be higher in frank 
diabetes and impaired glucose tolerance. And moreover elevated CRP levels have 
been found to be a risk factor for developing diabetes in the later part of life. Studies 
conducted by Festa et al have showed that there is a link between insulin resistance 
and CRP. Hyperglycemia promotes Oxidative stress on the endothelium which 
enhances inflammation. This mechanism has been supported by several studies which 
document an association between hyperglycemia and inflammation in diabetic 
patients.
20 
CRP AND CHOLESTEROL 
Cardiovascular risk is predicted by both cholesterol and CRP. However 
cholesterol cannot be used to predict the level of CRP and vice versa. Studies which 
were conducted predicting cardiovascular risk using both CRP and LDL cholesterol 
demonstrated that the risk was highest among those who had elevated levels of both 
CRP and LDL cholesterol. The risk was intermediate for those who had either one 
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elevated when compared to those who had both CRP and LDL low. This study 
showed that without CRP evaluation and relying only on cholesterol many people in 
the intermediate risk category with CRP alone positive will be missed for primary 
prevention.
3 
LDL is a critical risk factor for heart diseases and lowering LDL cholesterol is 
important in prevention of cardiovascular diseases. However more than LDL , CRP 
serves as a overall strong predictor for cardiovascular diseases and stroke. A decision 
to test for CRP in many ways is similar to test for cholesterol. Knowledge that levels 
of CRP are high should motivate one to be on diet, to do exercise , to lose weight and 
to stop smoking. All these changes in lifestyle lower CRP levels and in turn lower the 
risk of one getting heart diseases.
53
  
Role in hypertension  
According to the WOMEN’S HEALTH STUDY of over 20000 female health 
professionals in united states, who had no history of hypertension and had a base line 
blood pressure of less than 140/90 mm of hg were evaluated for the possible 
predictive value of CRP for the development of hypertension. Baseline CRP values 
were measured and the patients were followed up for a period of 7.8 years. It was 
found that about 11.5 percent of people developed hypertension. It was found out that 
with progressive increase in CRP values the risk of hypertension increased.
31
  
This study suggested that in the pathogenesis of hypertension, inflammation 
has a role. This might be related in part because of the association of metabolic 
syndrome and CRP. It is also postulated that CRP causes reduction of synthesis of 
nitric oxide in the endothelial cells causing a increase in the resistance in the vessels.
36
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Role in central obesity 
Inflammation in many overweight patients is because of central obesity or the 
tendency to put weight around the stomach. The fat cells or adipocytes produce 
messenger proteins which stimulates the production of CRP.
53
 This inflammation also 
leads to increased risk of diabetes. Thus central obesity predisposes to development of 
diabetes. Individuals with CRP value of greater than 3 mg/L have four to six times 
higher risk of developing diabetes.
29 
Role in metabolic syndrome 
People with metabolic syndrome are predisposed to develop heart diseases and 
diabetes. The main pathogenesis of metabolic syndrome is insulin resistance. CRP 
levels tend to increase with increase in number of components of metabolic syndrome. 
CRP levels tends to predict the risk of non diabetic metabolic syndrome patients 
developing diabetes. It also predicts the risk of developing coronary heart diseases in 
people with metabolic syndrome. CRP has now increasingly become a part of the 
process of defining metabolic syndrome.
3 
Role in stable coronary disease 
CRP has been found to be associated with atherosclerosis and increased levels 
of CRP reflect the increased risk of rupture of vulnerable plaques. CRP is associated 
with increased risk of developing future cardiac events in those who have stable 
angina. Most studies demonstrate a  strong relationship between baseline CRP values 
and risk of future coronary events.
38 
In PEACE trial about 3771 patients were 
evaluated. Patients with hs CRP were measured at baseline and followed up for a 
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mean period of 4.8 years for myocardial infarction, stroke or cardiovascular death. It 
was found out that a significantly higher risk of cardiovascular disease  was present in 
those who had a higher baseline CRP values, who were not on statin therapy  
compared to those who had a low value of CRP.
5 
In addition CRP values might predict the progression of coronary disease. A 
study was conducted in about 124 patients with stable chronic angina awaiting 
elective PCI and it was found out that elevated CRP was a independent predictor for 
progression of rapid coronary stenosis.
3 
Role in plaque rupture and ACS  
Plaque rupture followed by thrombus formation is the major primary 
pathophysiologic event in acute coronary syndrome. In ACS there is elevation of 
acute phase reactants such as CRP, IL- 6 which shows that there is chronic 
inflammation in the coronary arterial wall. These elevated levels of acute phase 
reactants are markers for underlying inflammation in the vessels and increased 
responsiveness of the inflammation even to very small stimuli.
10
 It was found that 
patients who had pre infarction unstable angina had higher levels of CRP and IL 6 
than those with unheralded myocardial infarction. It has been found out that there is 
association between elevated serum CRP level and plaque vulnerability and activity of 
coronary disease. Studies show that in patients with NSTEMI serum CRP levels were 
co related with a number of complex stenosis in vessels in angiography.
8 
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Prognosis after non-ST elevation ACS  
If the patients who have NSTEMI have elevated levels of CRP concentration at 
the time of admission and prior to discharge then they have a worse short and long 
term prognosis. Over 7000 NSTEMI patients were studied in the GUSTO IV ACS 
trial. It was found out that the patients in the fourth quartile of CRP had increased 30 
day mortality from 2 to 6.3 % when compared to those who had CRP in the first 
quartile. It was also found out that troponin T and CRP had complementary and 
independent prognostic significance. More over this study confirmed that when 
measured immediately after ACS CRP had a stronger predictor of mortality when 
compared to other factors.
10 
According to the PROVE IT- TIMI 22 trial which studied 4162 patients who 
were stabilized after ACS and followed up for a mean period of 24 months it was 
found out that those people who had  hs CRP greater than 2 mg/L had nearly a two 
fold higher risk of developing new or increased worsening of heart failure.
13
 A smaller 
TIMI 11A tril showed the predictive value of CRP and the interaction between CRP 
and troponin T. For those patients with ACS who undergo early revascularization it 
was found out that serum CRP was a independent predictor of short and long term 
mortality.
10 
Prognosis after acute MI  
After acute myocardial infarction the elevation of CRP levels indicate the 
extent of myocardial injury. Thus if CRP values are to be used for long term 
assessment of cardiovascular risk then the measurements have to be delayed by atleast 
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4 to 6 weeks to permit resolution of acute phase reactants. According to the 
THROMBO trial in which serum CRP values were assessed in 1045 patients two 
months after MI the patients in the highest quartile of CRP had increased rate of 
coronary events.
10 
Predictor of recurrent ischemia after CABG  
For patients who have underwent CABG for stable or unstable angina , it was 
found out those in those who had a elevated pre operative serum CRP > 3 mg/L had a 
significantly higher risk of new ischemic events.
17 
Predictor of adverse events after PCI  
In a study of 121 patients who underwent angioplasty it was found out that 
those people who had a high pre procedural value of serum CRP concentration  had a 
higher risk of both in hospital as well as intraprocedural complications and higher 
chance of restenosis at one year. Elevated levels of CRP before elective or urgent 
coronary stenting, have been associated with worse outcome because the stenting 
procedure itself can elicit an inflammatory response. A elevated preprocedural value is 
associated with 2.5 fold increased rate of myocardial infarction or death at 30 days 
following procedure, four fold increase in mortality at 20 months in those who 
undergo revascularisation, a five fold increase at the end of 3 years in unstable angina, 
myocardial infarction or death. It also leads to marked increased in progression of 
untreated lesions to significant stenosis.
28 
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Predictor in heart failure  
In patients who had heart failure, the values of CRP were elevated when 
compared to a general population. The likelihood of death progressively increased in 
those with elevated CRP levels. 
Predictor of sudden death  
According to a nested case control study by the PHYSICIANS HEALTH 
STUDY whish was a 17 year follow up study it was found out that people who had 
baseline CRP values in the highest quartile had the highest risk of sudden cardiac 
death.
27 
Predictor in cerebrovascular disease  
It has been found that CRP has been an independent marker for the progression 
of early carotid atherosclerotic disease and is associated with increased risk of 
ischemic stroke and is associated with poor prognosis following stroke. An elevated 
levels of CRP in patients with a ischemic stroke within the first 12 to 24 hours is 
associated with unfavourable outcomes.
30 
Predictor of cardiac allograft survival  
In those people who have had heart transplants, the leading cause of death or 
retransplantion is transplant coronary artery disease in those who survive more than 6 
months. Increased levels of has been found to be a marker of transplant vasculopathy 
and failure of allograft.
32  
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Role in Atrial Fibrillation  
The high incidence of AF following cardiac surgery suggest that an 
inflammatory process might play a role in the pathogenesis of atrial fibrillation. 
Elevated levels of CRP has been found in people with recent atrial arrhythmias, who 
fail cardioversion, who are likely to have recurrent AF and in person who are prone to 
develop new onset AF after cardioversion.
33 
METHODS TO LOWER CRP LEVELS 
The best way to lower CRP levels is to undergo lifestyle modifications. These 
include exercise, smoking cessation, blood pressure control and diet. Thus the most 
important role of measuring CRP levels is to identify people with high risk even with 
low cholesterol levels and to motivate them towards heart healthy inteventions. 
EFFECT OF THERAPY  
Undertaking certain modifications in diet and taking a number of drugs to treat 
cardiovascular diseases can reduce serum CRP levels.  
STATINS  
Effect on CRP 
In patients with hyperlipidemia, multiple statins decrease the serum CRP levels 
significantly. This effect is found to be independent of the decrease in serum LDL 
cholesterol levels. The mechanism by which statins reduce the levels of CRP is partly 
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by reducing the expression of IL-6 and tumour necrosis factor alpha by the monocytes 
and by direct suppression of transcription of CRP gene.
3
                                          
Statin therapy causes reduction of CRP levels both when used for primary 
prevention and for reduction of serum CRP after an ACS. As early as 14 days after 
starting statin therapy serum CRP levels tend to fall. In review of literature of about 
thirteen controlled trials it was found out that serum CRP levels are reduced from 13 
to 50 percent with statin therapy as compared to placebo therapy. And according to 
five studies comparing different statins it was found out that there was no advantage 
of one statin over another in reducing the CRP levels. According to the phase Z of the 
A to Z trial, a modestly greater reduction in CRP levels was found with intensive 
statin therapy.
22 
REDUCTION IN CORONARY RISK 
Several studies have co related that elevated CRP levels is associated with 
increased cardiovascular risk. Stains because of their anti-inflammatory action are 
postulated to reduce the risk of cardiovascular events. Several studies have been 
conducted to support this concept.
43 
In studies conducted in patients undergoing PCI it was found out that satin 
therapy benefit was seen in those who had higher quartile of CRP levels. According to 
the AFCAPS/ TEXCAPS trial of primary prevention it was found out that  CRP levels 
are reduced by almost 15 percent by using lovastatin. Reduction in coronary events on 
using statin was found not only in those with deranged lipid parameters but also who 
had normal LDL- HDL ratio with elevated CRP levels. 
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According to phase Z of A to Z trial it was shown that lower level of hs CRP at end of 
thirty days and at the end of four months after a acute coronary syndrome were 
associated with increased long term survival and those patients who received 
aggressive statin therapy were  found to have more likelihood of achieving lower hs 
CRP levels.
18 
A higher two year mortality was found in patients who at the end of 30 days 
had a hs CRP levels of greater than 3 mg/L when compared to those who had a hs 
CRP levels less than 1 mg/L. It was found out that patients who were given intensive 
statin therapy were more likelihood of achieving lower values less than 1 mg/L at the 
end of 30 days and four months.
22 
According to PROVE IT- TIMI 22 trail in which about 4162 patients with ACS 
were randomly assigned to either 80 mg/day of atorvastatin or 40 mg/kg of 
pravastatin. It was found out that at the end of thirty days significant reductions was 
achieved in levels of CRP in both groups. And a linear relationship was found to exist 
between the levels of CRP levels attained after statin therapy the risk of developing 
recurrent myocardial infarction or coronary deaths.  
According to REVERSAL trial in which about 502 patients were studied, 
intravascular ultrasonography was used to monitor the progression of atherosclerosis 
in patients with angiographic coronary disease. It was found out those the patients in 
the group who received stains had a significantly slower progression of atherosclerosis 
and maximum regression was seen in those who had the greatest fall in the levels of 
CRP.
18 
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According to JUPITER trial, patients with LDL value less than 130 mg/dl and 
CRP level higher than 2 mg/L were assigned into two groups, once which received 
rosuvastatin 20 mg daily and other which received placebo. It was found out that the 
treated group had better clinical outcomes.
46 
Antiplatelet agents 
Aspirin  
According to Physician’s Health study it was found out that the cardiovascular 
risk reduction in those taking aspirin is maximum among those who belong to the high 
quartile of serum CRP group. This observation suggests that the cardiovascular risk 
reducing benefit of aspirin is due to its anti inflammatory action as well as the its 
antiplatelet action. 
According to a study conducted in patients with stable angina who were put 
into two groups one receiving aspirin and other receiving placebo it was found out that 
after six weeks aspirin therapy lowered the levels of elevated CRP and other 
proinflammatory cytokines.
37 
GP IIb/IIIa inhibitors 
After acute percutaneous coronary intervention it was found out that 
Abciximab reduces the risk of an acute ischemic event. The anti inflammatory action 
might contribute to this effect. According to a study conducted with 160 patients it 
was found out that abciximab decreased the transient increase in serum CRP , TNF 
alpha and IL-6 induced by angioplasty.
40 
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Thiazolidinediones  
Reduction in serum CRP concentrations in patients with or without type 2 
diabetes is achieved with both pioglitazone and rosiglitazone. This effect is 
independent of the glycemic control.  In PIOSTAT trial about 125 patients who are 
non diabetic with elevated CRP and cardiovascular diseases were assigned to three 
groups. One group were assigned to pioglitazone with placebo, second group were 
assigned to simvastatin with placebo and third group were assigned to a combination 
of pioglitazone and simvastatin . it was found out that significant reduction in CRP 
levels are found with pioglitazone and simvastatin as monotherapy and combination 
therapy had additive effect.
44 
Dietary modification 
Studies have shown that certain dietary modifications are found to lower serum 
CRP levels. It was found out that the diet rich in viscous fibre, plant sterols, soy 
protein and nuts with low levels of calorie and fat restriction were found to reduce 
serum CRP levels. And addition of statin to the diet has been found to drastically 
decrease the levels of serum CRP.
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3. AIMS AND OBJECTIVES OF STUDY 
1. To test association between  hs CRP and various individual components of 
metabolic syndrome 
2. To test the association between  hs CRP and metabolic syndrome 
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4. MATERIALS AND METHOD 
Place of study 
Stanley Medical College and Hospital, Chennai 
Department of General Medicine, OPD, Medical wards 
Study population 
       50 consecutive patients of metabolic syndrome 
Study design-  
Prospective and observational  Study 
ETHICAL COMMITTEE APPROVAL 
Ethical committee approval was obtained for the study  
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OPERATIONAL DEFINITIONS  
Case definition:  
1)Metabolic syndrome- was defined   the presence of at least 3 of the following 
criteria: 
 The cut-off point of waist circumference is  ≥90 cm in men and ≥80 cm in women 
according to the recommendation by the World Health Organization (WHO) 
guidelines for South Asians
41 
  Triglycerides ≥150 mg/dL or treatment for hypertriglyceridemia. 
  HDL-C < 40 mg/dL in men or <50 mg/mL in women or treatment for low HDL-
C.  
  Blood pressure ≥130/85 mmHg or treatment for hypertension 
  Fasting glucose ≥100 mg/dL or treatment for hyperglycemia15 
2) High sensitivity CRP (hs.CRP) levels were measured by enzyme-linked 
immunosorbent assay, and defined as high when >3 mg/L.
23 
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PATIENT SELECTION 
 Inclusion criteria 
1) metabolic syndrome diagnosed  patients according to the NCEP ATP 111 criteria 
considering abdominal obesity as per World Health Organization (WHO) guidelines 
for South Asians 
2) Age –more than 20 years2 
Exclusion criteria 
1) Patients takings statins, asprin, thiazolidinediones,  
2) Patients with acute infections 
3) Patients with chronic inflammatory conditions like inflammatory bowel 
disease, osteoarthritis, rheumatoid arthritis, gout, bronchial asthma and chronic 
hepatits  
4) Patients with acute myocardial infarction , cerebral infarction 
5) Patients with chronic kidney disease2 
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Methodology 
            Patients aged above 20 years presenting to the Medicine out-patient service 
and those admitted to the medical wards at Stanley medical college hospital Chennai  
were included in the present study. The data were recorded from each subject with an 
in-person interview by administering a specific questionnaire. The components of 
metabolic syndrome were defined according to the modified National Cholesterol 
Education Program Adult Treatment Panel III (NCEP-ATP III) criteria considering 
abdominal obesity as per World Health Organization (WHO) guidelines for South 
Asians. Waist circumference was measured using a non-elastic measuring tape at the 
highest level of iliac crest with the patient standing with feet 1 foot apart. Systolic and 
diastolic blood pressure was measured by sphygmomanometer. Individuals reporting a 
history of hypertension and current antihypertensive medication use were defined as 
having hypertension regardless of the blood pressure values measured at the time of 
evaluation. Diabetes mellitus was diagnosed as per the American Diabetic Association 
(ADA) diagnostic criteria and/or concomitant anti-diabetic treatment, regardless of the 
measured glucose values.
4 
In all the patients, a peripheral venous blood sample was to be drawn in the morning 
after 8 - 10 hours of fasting, to measure venous plasma glucose, serum total 
cholesterol, serum high density lipoprotein (HDL) cholesterol, and serum triglyceride 
levels. Serum glucose was to be measured by the glucose oxidase method; plasma 
triglycerides, total cholesterol and HDL-cholesterol were to be measured by 
enzymatic colorimetric assay using autoanalyser.
19
 Serum hs-CRP levels were to be 
determined by immune-turbidometric assay using with dedicated reagents . We used 
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CRP cut-off values of 3.0 mg/l, as recommended by the Centers for Disease Control 
and the American Heart Association. The study period is from January 2015 to may 
2015.
2 
HUMAN SUBJECT PROTECTION: 
The full protocol along with draft questionnaire and Informed consent will be 
kept in Institutional ethical Committee and approval will be obtained.  
INFORMED CONSENT: 
 Consent form will be written in both English and Tamil and consent will be 
obtained from the participant, confidentiality will be maintained. 
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5. RESULTS AND DISCUSSIONS 
Data Analysis 
The patients were divided into two groups - hs-CRP negative Group and hs-CRP 
positive Group.  Descriptive statistics was done for all data and were reported in terms 
of mean values and percentages. Suitable statistical tests of comparison were done. 
Continuous variables were analysed with the unpaired t test. Categorical variables 
were analysed with Fisher Exact Test. Statistical significance was taken as P < 0.05. 
The data was analysed using SPSS version 16 and Microsoft Excel 2007. 
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Sample Size Calculation 
Sample size was determined based on the study “Highly sensitive C-reactive 
protein in metabolic syndrome” authored by  Sudha Vidyasagar et al. and published in 
JIACM 2013; 14(3-4): 230-4. In this study the On univariate analysis, hs-CRP was 
found to be significantly increased in patients with diabetes mellitus (86%)(p < 0.021) 
 
The confidence level is estimated at 95% with a z value of 1.96 and the 
confidence interval or margin of error is estimated at +/-10. Assuming p = 86%  and 
q= 14%. 
n=p x q x [z/e] ² 
n= 86 x 14 x [1.96/12]² 
n= 46.25 
Therefore 46 is the minimum sample size required for the study.  
 In our study we have taken 50 as the sample size  
 n=14  in  hs-CRP negative Group 
 n=36 in  hs-CRP positive Group 
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Age  
 
Age Distribution hs-CRP -Ve % hs-CRP +ve % 
21-40 Years 5 31.25 5 14.71 
41-60 Years 8 50.00 18 52.94 
> 60 years 3 18.75 11 32.35 
Total 16 100 34 100 
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Age Distribution hs-CRP -Ve hs-CRP +ve 
N 16 34 
Mean 46.63 55.35 
SD 11.41 14.23 
P value  
Unpaired t Test 
0.1258 
 
DISCUSSION 
Majority of the hs-CRP -Ve Group patients belonged to the 41-60 Years age 
class interval (n=8, 50.00%) with a mean age of 46.63 years. In the hs-CRP +Ve 
group patients, majority belonged to the 41-60 years age class interval (n=18, 52.94%) 
with a mean age of 55.35 years. The association between the study groups and age 
distribution is considered to be not statistically significant since p > 0.05 as per  2 tail 
unpaired t test. 
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Gender  
 
 
Gender 
Distribution 
hs-CRP -Ve % hs-CRP +ve % 
Male 10 62.50 11 32.35 
Female 6 37.50 23 67.65 
Total 16 100 34 100 
P value 
Fishers Exact Test 
0.1439 
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DISCUSSION 
Majority of the hs-CRP -Ve Group Group patients belonged to the male gender 
group (n=10, 62.50%). In the hs-CRP +Ve group patients, majority belonged to the 
female gender group (n=23, 67.65%). The association between the study groups and 
gender distribution is considered to be not statistically significant since p > 0.05 as per 
Fishers Exact test. 
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Diabetes Mellitus Status 
 
 
Diabetes Mellitus 
Status 
hs-CRP -Ve % hs-CRP +ve % 
Non Diabetic 9 56.25 5 14.71 
Diabetic 7 43.75 29 85.29 
Total 16 100 34 100 
P value  
Fishers Exact Test 
0.0023* 
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DISCUSSION 
There is a true difference among study groups study groups in relation to 
diabetes mellitus status and this difference is considered to be statistically significant 
since p < 0.05 as per fishers exact test. In simple terms, Most of the hs-CRP -Ve 
Group patients are non diabetics (n=9, 56.25%). In the hs-CRP +Ve Group patients, 
majority were diabetics (n=29, 85.29%). This diabetes mellitus status distribution 
among the study groups expressed a p-value of 0.0001.  The incidence of diabetes 
mellitus was meaningfully less in hs-CRP -Ve Group compared to hs-CRP +Ve Group 
by 41.54 percentage points. This significant difference of 1.95 times increase in 
incidence of diabetes mellitus in hs-CRP +Ve Group compared to hs-CRP -Ve Group 
is true and has not occurred by chance. In this study we can safely conclude that hs-
CRP positivity results in significantly increased incidence of diabetes mellitus 
compared to hs-CRP negativity in metabolic syndrome patients.  
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Duration of Diabetes 
 
 
Duration of 
Diabetes 
hs-CRP -Ve % hs-CRP +ve % 
≤ 5 Years 3 42.86 6 20.69 
6-10 Years 2 28.57 9 31.03 
11-15 Years 2 28.57 7 24.14 
16-20 Years 0 0.00 3 10.34 
> 20 Years 0 0.00 4 13.79 
Total 7 100 29 100 
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Duration of Diabetes hs-CRP -Ve hs-CRP +ve 
N 7 29 
Mean 7.00 10.86 
SD 4.28 6.27 
P value 
Unpaired t Test 
0.0446* 
 
DISCUSSION 
There is a true difference among study groups study groups in relation to 
duration of diabetes mellitus and this difference is considered to be statistically 
significant since p < 0.05 as per unpaired t test. In simple terms, Most of the hs-CRP -
Ve Group patients belonged to the ≤ 5 Years duration of diabetes class interval (n=9, 
56.25%) with a mean duration of 7 years. In the hs-CRP +Ve Group patients, majority 
belonged to the 6-10 Years duration of diabetes class interval (n=9, 31.03%) with a 
mean duration of 10.86 years. 
This duration of diabetes mellitus distribution among the study groups 
expressed a p-value of 0.0446.  The duration of diabetes mellitus was meaningfully 
less in hs-CRP -Ve Group compared to hs-CRP +Ve Group by 4.29 years. This 
significant difference of 1.65 times increase in incidence of diabetes mellitus in hs-
CRP +Ve Group compared to hs-CRP -Ve Group is true and has not occurred by 
chance. In this study we can safely conclude that hs-CRP positivity is significantly 
increased in metabolic syndrome patients with longer duration of diabetes mellitus 
compared to hs-CRP negativity which occurs more in metabolic syndrome patients 
with lesser duration of diabetes mellitus.   
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Diabetes Control Status 
 
Diabetes Control 
Status 
hs-CRP -Ve % hs-CRP +ve % 
Controlled 6 85.71 11 37.93 
Uncontrolled 1 14.29 18 62.07 
Total 7 100 29 100 
P value 
Fishers Exact Test 
0.0365* 
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DISCUSSION 
There is a true difference among study groups study groups in relation to 
diabetes mellitus control status and this difference is considered to be statistically 
significant since p < 0.05 as per fishers exact test. In simple terms, Most of the hs-
CRP -Ve Group patients who are diabetics, are under strict blood glucose control 
(n=6, 85.71%). In the hs-CRP +Ve Group patients who are diabetics, majority are not 
under strict blood glucose control (n=18, 62.07%). This control of blood sugar in 
diabetics among the study groups is expressed with a p-value of 0.0365.  The 
incidence of strict blood glucose control among diabetics was meaningfully more in 
hs-CRP -Ve Group compared to hs-CRP +Ve Group by 47.78 percentage points. This 
significant difference of 2.26 times increase in incidence of diabetes mellitus in hs-
CRP -Ve Group compared to hs-CRP +Ve Group is true and has not occurred by 
chance. In this study we can safely conclude that strict blood glucose control among 
diabetics in metabolic syndrome patients results in hs-CRP negativity and poor blood 
glucose control among diabetics in metabolic syndrome patients results in hs-CRP 
positivity.   
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Hypertension Status 
 
Hypertension Status hs-CRP -Ve % hs-CRP +ve % 
Non Hypertensive 2 12.50 11 32.35 
Hypertensive 14 87.50 23 67.65 
Total 16 100 34 100 
P value  
Fishers Exact Test 
0.1792 
 
DISCUSSION 
Majority of the hs-CRP -Ve Group Group patients were hypertensives (n=14, 
87.50%). In the hs-CRP +Ve group patients, majority were hypertensives (n=23, 
67.65%). The association between the study groups and hypertension status is 
considered to be not statistically significant since p > 0.05 as per Fishers Exact test. 
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Duration of Hypertension 
 
Duration of 
Hypertension 
hs-CRP -Ve % hs-CRP +ve % 
≤ 5 Years 8 57.14 10 43.48 
6-10 Years 4 28.57 5 21.74 
11-15 Years 2 14.29 6 26.09 
16-20 Years 0 0.00 2 8.70 
> 20 Years 0 0.00 0 0.00 
Total 14 100 23 100 
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Duration of Hypertension hs-CRP -Ve hs-CRP +ve 
N 14 23 
Mean 6.36 8.09 
SD 3.86 5.12 
P value 
Unpaired t Test 
0.2518 
 
DISCUSSION 
Majority of the hs-CRP -Ve Group patients belonged to the ≤ 5 Years duration 
of hypertension class interval (n=8, 57.14%) with a mean duration of 6.36 years. In 
the hs-CRP +Ve group patients, majority belonged to the ≤ 5 Years duration of 
hypertension class interval (n=10, 43.48%) with a mean duration of 8.09 years. The 
association between the study groups and duration of hypertension is considered to be 
not statistically significant since p > 0.05 as per  2 tail unpaired t test. 
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Hypertension Control status 
 
 
Hypertension 
Control status 
hs-CRP -Ve % hs-CRP +ve % 
Controlled 10 71.43 17 73.91 
Uncontrolled 4 28.57 6 26.09 
Total 14 100 23 100 
P value 
Fishers Exact Test 
0.2883 
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DISCUSSION 
Majority of the hs-CRP -Ve Group hypertensive patients were under strict 
control (n=10, 71.43%). In the hs-CRP +Ve group hypertensive patients, majority 
were under strict control (n=17, 73.91%). The association between the study groups 
and hypertension control status is considered to be not statistically significant since p 
> 0.05 as per Fishers Exact test. 
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Abdominal Diameter 
 
 
 
Abdominal 
Diameter 
hs-CRP -Ve % hs-CRP +ve % 
Normal 10 62.50 5 14.71 
Abnormal 6 37.50 29 85.29 
Total 16 100 34 100 
P value  
Fishers Exact Test 
0.0019* 
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DISCUSSION 
There is a true difference among study groups study groups in relation to 
abdominal diameter status and this difference is considered to be statistically 
significant since p < 0.05 as per fishers exact test. In simple terms, Most of the hs-
CRP -Ve Group patients had normal abdominal diameter (n=10, 62.50%). In the hs-
CRP +Ve Group patients, majority had abnormal abdominal diameter (n=29, 85.29%). 
This abnormality in abdominal diameter among the study groups is expressed with a 
p-value of 0.0019.  The incidence of abnormal abdominal diameter was meaningfully 
less in hs-CRP -Ve Group compared to hs-CRP +Ve Group by 47.79 percentage 
points. This significant difference of 2.27 times increase in incidence of abnormal 
abdominal diameter in hs-CRP +Ve Group compared to hs-CRP -Ve Group is true and 
has not occurred by chance. In this study we can safely conclude that abnormal 
abdominal diameter in metabolic syndrome patients results in higher hs-CRP 
positivity and normal abdominal diameter in metabolic syndrome patients results in 
higher hs-CRP negativity.   
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Serum Triglycerides 
 
 
 
Serum 
Triglycerides 
hs-CRP -Ve % hs-CRP +ve % 
Normal 2 12.50 4 11.76 
Abnormal 14 87.50 30 88.24 
Total 16 100 34 100 
P value  
Fishers Exact Test 
>0.9999 
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DISCUSSION 
Majority of the hs-CRP -Ve Group patients had abnormal triglyceride levels 
(n=14, 87.50%). In the hs-CRP +Ve group patients, majority had abnormal 
triglyceride levels (n=30, 88.24%). The association between the study groups and 
serum triglyceride levels is considered to be not statistically significant since p > 0.05 
as per Fishers Exact test. 
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Serum HDL 
 
Serum HDL hs-CRP -Ve % hs-CRP +ve % 
Normal 8 50.00 13 38.24 
Abnormal 8 50.00 21 61.76 
Total 16 100 34 100 
P value  
Fishers Exact Test 
0.3653 
 
DISCUSSION 
Majority of the hs-CRP -Ve Group patients had abnormal HDL levels (n=8, 
50.00%). In the hs-CRP +Ve group patients, majority had abnormal HDL levels 
(n=21, 61.76%). The association between the study groups and serum HDL levels is 
considered to be not statistically significant since p > 0.05 as per Fishers Exact test. 
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Exercise Status 
 
 
 
Exercise 
Status 
hs-CRP -Ve % hs-CRP +ve % 
No 8 50.00 25 73.53 
Yes 8 50.00 9 26.47 
Total 16 100 34 100 
P value  
Fishers Exact Test 
0.0426* 
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DISCUSSION 
There is a true difference among study groups study groups in relation to 
exercise status and this difference is considered to be statistically significant since p < 
0.05 as per fishers exact test. In simple terms, Most of the hs-CRP -Ve Group patients 
exercised regularly (n=8, 50.00%). In the hs-CRP +Ve Group patients, majority did 
not exercise regularly (n=25, 73.53%). This abnormality in exercise status among the 
study groups is expressed with a p-value of 0.0426.  The incidence of exercising 
regularly was meaningfully more in hs-CRP -Ve Group compared to hs-CRP +Ve 
Group by 23.53 percentage points. This significant difference of 1.89 times increase in 
incidence of exercising regularly in hs-CRP -Ve Group compared to hs-CRP +Ve 
Group is true and has not occurred by chance. In this study we can safely conclude 
that exercising regularly in metabolic syndrome patients results in higher hs-CRP 
negativity and not exercising regularly in metabolic syndrome patients results in 
higher hs-CRP positivity.   
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Smoking Status 
 
Smoking 
Status 
hs-CRP -Ve % hs-CRP +ve % 
No 12 75.00 28 82.35 
Yes 4 25.00 6 17.65 
Total 16 100 34 100 
P value  
Fishers Exact Test 
0.7067 
 
DISCUSSION 
Majority of the hs-CRP -Ve Group patients were non smokers (n=12, 75.00%). 
In the hs-CRP +Ve group patients, majority were non smokers (n=28, 82.35%). The 
association between the study groups and smoking status is considered to be not 
statistically significant since p > 0.05 as per Fishers Exact test. 
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Metabolic Syndrome - Number of Criteria Met 
 
 
 
Metabolic Syndrome - 
Number of Criteria 
met 
hs-CRP -Ve % hs-CRP +ve % 
Three 15 93.75 11 32.35 
Four 1 6.25 18 52.94 
Five 0 0.00 5 14.71 
Total 16 100 34 100 
P value  
Fishers Exact Test 
0.0001 
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DISCUSSION 
There is a true difference among study groups study groups in relation to 
number of metabolic syndrome criteria met and this difference is considered to be 
statistically significant since p < 0.05 as per fishers exact test. In simple terms, Most 
of the hs-CRP -Ve Group patients had three metabolic syndrome criteria met (n=15, 
93.75%). In the hs-CRP +Ve Group patients, majority had four metabolic syndrome 
criteria met did not exercise regularly (n=18, 52.94%). This difference in metabolic 
syndrome criteria met among the study groups is expressed with a p-value of 0.0001.   
Three metabolic syndrome criteria met was meaningfully more in hs-CRP -Ve 
Group compared to hs-CRP +Ve Group by 61.40 percentage points. Four metabolic 
syndrome criteria met was meaningfully less in hs-CRP -Ve Group compared to hs-
CRP +Ve Group by 46.69 percentage points. Five metabolic syndrome criteria met 
was meaningfully less in hs-CRP -Ve Group compared to hs-CRP +Ve Group by 
14.71 percentage points. This significant difference of 2.90 times increase in incidence 
of three metabolic syndrome criteria met, 88% decrease in incidence of four metabolic 
syndrome criteria met in hs-CRP -Ve Group compared to hs-CRP +Ve Group,  is true 
and has not occurred by chance. In this study we can safely conclude that increase in 
number of metabolic syndrome criteria met in metabolic syndrome patient’s results in 
higher hs-CRP positivity and decrease in number of metabolic syndrome criteria met 
in metabolic syndrome patient’s results in higher hs-CRP negativity.   
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Diet Status 
 
Diet Status hs-CRP -Ve % hs-CRP +ve % 
Vegetarian 3 18.75 2 5.88 
Non Vegetarian 13 81.25 32 94.12 
Total 16 100 34 100 
P value  
Fishers Exact Test 
0.3109 
 
DISCUSSION 
Majority of the hs-CRP -Ve Group patients were non vegetarians (n=13, 
81.25%). In the hs-CRP +Ve group patients, majority were non vegetarians (n=32, 
94.12%). The association between the study groups and diet status is considered to be 
not statistically significant since p > 0.05 as per Fishers Exact test. 
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Metabolic Syndrome Vs 
CRP 
Metabolic Syndrome 
Cases 
Percentage 
hs-CRP +ve 34 68 
hs-CRP –Ve 16 32 
Total 50 100 
 
About 34 patients had tested positive for Hs CRP in total 50 metabolic 
syndrome patients. This shows us that there is a 68 % association of CRP with 
metabolic syndrome 
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CONCLUSIONS 
The following were the conclusion of this study 
1. The association between the study groups and age distribution is considered to 
be not statistically significant. 
2. The association between the study groups and gender distribution is considered 
to be not statistically significant 
3. hs-CRP has a positive correlation with increased incidence of diabetes mellitus. 
4. hs-CRP has a positive correlation with longer duration of diabetes mellitus. 
5. Strict glycemic control among diabetics in metabolic syndrome patients is 
found to have a negative correlation with hs CRP.   
6. Association between the study groups and hypertension status is considered to 
be not statistically significant 
7. Abnormal abdominal diameter in metabolic syndrome patients is found to have 
a positive correlation with hs CRP.   
8. Association between the study groups and serum triglyceride levels is 
considered to be not statistically significant 
9. Association between the study groups and serum HDL levels is considered to 
be not statistically significant 
10. Exercising regularly in metabolic syndrome patients is found to have a negative 
correlation with hs CRP.   
11. Association between the study groups and smoking status is considered to be 
not statistically significant. 
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12. Increase in number of metabolic syndrome criteria met in metabolic syndrome 
patient’s is found to have a positive correlation with hs CRP.     
13. The association between the study groups and diet status is considered to be not 
statistically significant. 
14. hs CRP was found to be elevated in two thirds (68%) of patients with metabolic 
syndrome. 
SUMMARY 
Thus there is positive correlation of hs CRP with diabetes, duration of diabetes, 
abnormal abdominal diameter and number of metabolic syndrome criteria met. 
There is a negative correlation of hs CRP with strict glycemic control and 
exercise. 
Thus there is no statistical significant correlation of hs CRP with age gender, 
hypertension, serum triglyceride levels, serum HDL level, smoking and diet status.  
Thus we can safely conclude that about two third patients with metabolic 
syndrome have elevated levels of hs CRP.  
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2. PROFORMA 
NAME:                                             
AGE: 1. 25-40yrs   2. 40-60yrs  3. >60                                  SEX: 1.M   2.F 
LOCALITY:                                                                        CONTACT NO: 
COMPLAINTS             : 
PAST H/O  DIABETES:                            1. Yes          2. No  If yes specify_________ 
         HYPERTENSION          1. Yes          2. No  If yes specify_________ 
                    RENAL FAILURE          1. Yes          2. No  If yes specify_________ 
          AUTOIMMUNE DISORDER 1. Yes        2. No  If yes specify_________ 
          CARDIAC ILLNESS          1. Yes        2. No  If yes specify_________ 
                    STROKE                                1. Yes        2. No  If yes specify_________ 
                    CONNECTIVE TISSUES        1. Yes        2. No  If yes specify_________  
                                          DISORDER 
                    INFLAMMATORY BOWEL 1. Yes        2. No  If yes specify_________ 
                                           DISEASE 
                    OSTEOARTHRITIES ,           1. Yes        2. No  If yes specify_________ 
                    RHEUMATOID ARTHRITIS1. Yes        2. No  If yes specify_________ 
                   GOUT                                      1. Yes        2. No  If yes specify_________   
                   BRONCHIAL ASTHMA           1. Yes        2. No  If yes specify_________ 
         OTHERS           _______________________ 
H/O CHRONIC DRUG INTAKE: 
 
H/O OF ANY RECENT FEVER : 1. YES  2 .NO 
PERSONAL H/O 
FOOD  :                       1.veg  2.Non veg 
SMOKING              :  1. Yes   2. No 
ALCOHOL INTAKE: 1. Yes 2. No 
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EXERCISE OF ATLEAST 30 MINS FOR 5 DAYS A WEEK : 1. Yes 2. No 
VITALS-  
 BP:                                      PR:                          RR:                        TEMPERATURE-  
SYSTEMIC EXAMINATION-  
CVS:                                                           RS:                                              PA: 
CNS: 
 
                                             INVESTIGATIONS 
 
CBC            : 
RFT : 
FBS : 
LIPID  PROFILE  : 
 
ECG FINDINGS: 
hs CRP - 
METABOLIC SYNDROME CRITERIA 
HYPERTENSION     : 1. Yes 2. No                BP-         Duration- 
DIABETES                :  1. Yes 2. No                FBS-        Duration 
WAIST CIRCUMFERENCE:    
HDL-  
TRIGLYCERIDES-  
NO OF CRITERIA SATISFIED -  
 
 
 
COMMENT:  
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3. CONSENT FORM              
                     GOVT. STANLEY MEDICAL COLLEGE, CHENNAI – 600001 
INFORMED CONSENT 
A STUDY ASSOCIATION OF hs CRP IN METABOLIC SYNDROME 
PATIENTS  
 AT GOVERNMENT STANLEY MEDICAL COLLEGE HOSPITAL, CHENNAI. 
 
Place of study:  Govt. Stanley medical college, Chennai 
I ……………………………………………. have been informed about the details of the study in my own 
language. 
I have completely understood the details of the study. 
I am aware of the possible risks and benefits, while taking part in the study. 
I agree to collect samples of blood/saliva/urine/tissue if study needs. 
I understand that I can withdraw from the study at any point of time and even then, I can receive the 
medical treatment as usual. 
I understand that I will not get any money for taking part in the study. 
I will not object if the results of this study are getting published in any medical journal, provided my 
personal identity is not revealed. 
I know what I am supposed to do by taking part in this study and I assure that I would extend my full 
cooperation for this study.   
  
 
 Volunteer:       Witness: 
Name and address        Name and address  
Signature/thumb impression:     Signature/thumb impression 
Date:        Date: 
  
Investigator Signature and date 
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                         GOVT. STANLEY MEDICAL COLLEGE, CHENNAI – 600001 
INFORMED CONSENT 
 
வளர்சிதை மாற்ற ந ாய்க்குறி ந ாயாளிகளுக்கு அைிகபட்ச CRP பற்றிய 
ஒரு ஆய்வு சங்கம் 
 
நான் இந்த ஆராய்ச்சியில் விவரங்களை முற்றிலும் புாிந்து ககாண்டேன். 
ஆய்வில் பங்கு எடுத்து டபாது, சாத்தியமான அபாயங்கள் மற்றும் பயன்களை பற்றி நான் 
அறிந்துள்டைன். 
நான் எந்தகவாரு டவளையிலும் ஆய்வில் இருந்து திரும்ப முடியும், அதன் பின்னர், நான் 
வழக்கம் டபால் மருத்துவ சிகிச்ளச கபற முடியும் என்று புாிந்துககாள்கிடறன் 
நான் ஆய்வில் பங்கு எடுத்து பணம் எளதயும் கபற முடியாது என்று அறிந்துள்டைன். 
இந்த ஆய்வின் முடிவுகள் எந்த கமடிக்கல் ஜர்னலில் கவைியிேப்பே இருந்தால் நான் 
எதிர்க்கவில்ளை, என் தனிப்பட்ே அளேயாைத்ளத கவைிப்படுத்தப்பட்டு இருக்க கூோது. 
நான் இந்த ஆய்வில் பங்ககடுப்பதன் மூைம் நான் என்ன கசய்ய டபாகிடறன் என்று கதாியும் 
நான் இந்த ஆய்வில் என் முழு ஒத்துளழப்ளபயும் ககாடுப்டபன் என்று உறுதியைிக்கிடறன். 
 
 
தன்னார்வைர்           சாட்சி  
கபயர் மற்றும் முகவாி       கபயர் மற்றும் முகவாி 
ளககயாப்பம் / விரல் டரளக:      ளககயாப்பம் / விரல் டரளக: 
 
 
 
ஆராய்ச்சியாைராக 
ளககயாப்பம் மற்றும் டததி  
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4. ETHICAL COMMITTEE APPROVAL LETTER 
 
 
 
 
 
9
2
 
 
5
. 
M
A
ST
ER
 C
H
A
R
T 
SL
 
N
O
 
A
G
E 
SE
X
 
D
IA
B
ET
IC
 
H
YP
ER
TE
N
SI
O
N
 
A
B
 
D
IA
M
E 
TG
L 
H
D
L 
 
EX
ER
IC
SE
 
SM
O
K
IN
G
 
N
O
 O
F 
FA
C
TO
R
S 
N
V
 
h
s 
C
R
P
 
 
 
 
Y 
 O
R
 
N
 
D
U
R
A
TI
O
N
 
C
 O
R
 
U
C
 
Y 
O
R
 
N
 
D
U
R
A
TI
O
N
 
C
 O
R
 
U
C
 
Y 
O
R
 N
 
Y 
O
R
 
N
 
Y 
O
R
 N
 
Y 
O
R
 N
 
Y 
O
R
 N
 
 
Y 
O
R
 N
 
Y
 O
R
 N
 
1 
5
6
 
F 
Y 
 
1
2 
U
C
 
N
 
 
 
Y-
 1
0
0
 
Y-
2
7
4
 
Y-
4
7 
N
 
N
 
4
 
Y 
Y
 
2 
6
9
 
M
 
Y 
1
5 
C
 
Y 
1
5 
C
 
N
 
Y-
1
7
0
 
N
 
N
 
Y 
3
 
Y 
Y
 
3 
3
5
 
M
 
N
 
 
 
N
 
 
 
Y-
9
8
 
Y-
1
6
0
 
Y-
3
5 
Y 
N
 
3
 
Y 
N
 
4 
4
8
 
F 
Y 
5 
Y 
Y 
4 
U
 
Y-
9
0
 
Y-
2
1
0
 
Y-
4
4 
N
 
N
 
5
 
Y 
Y
 
5 
4
1
 
M
 
N
 
 
 
Y 
 
 
Y-
9
6
 
Y-
1
9
6
 
N
 
Y 
N
 
3
 
N
 
N
 
6 
2
7
 
F 
N
 
 
 
N
 
 
 
Y-
8
8
 
Y-
2
4
0
 
Y-
3
1 
N
 
N
 
3
 
Y 
Y
 
7 
5
5
 
M
 
Y 
1
1 
U
 
Y 
1
2 
C
 
Y-
9
4
 
N
 
Y-
3
4 
N
 
Y 
4
 
Y 
Y
 
8 
6
9
 
F 
Y 
1
8 
U
 
N
 
 
 
Y-
1
0
9
 
Y-
2
8
4
 
Y-
2
9 
Y 
N
 
4
 
Y 
Y
 
9 
4
5
 
F 
Y 
2 
C
 
Y 
5 
C
 
N
 
Y-
2
7
4
 
N
 
Y 
N
 
3
 
Y 
N
 
1
0 
5
2
 
F 
Y 
6 
U
 
N
 
 
 
Y-
1
1
4
 
Y-
1
9
8
 
Y-
3
1 
N
 
N
 
4
 
Y 
Y
 
1
1 
4
5
 
F 
N
 
 
 
Y 
3 
C
 
Y-
9
5
 
Y-
2
7
4
 
Y-
2
8 
Y 
N
 
4
 
Y 
Y
 
1
2 
5
2
 
M
 
N
 
 
 
Y 
5 
U
 
Y-
9
9
 
Y-
2
2
1
 
N
 
Y 
N
 
3
 
Y 
N
 
1
3 
2
9
 
F 
N
 
 
 
N
 
 
 
Y-
1
1
9
 
Y-
2
4
6
 
Y-
 3
9
 
N
 
N
 
3
 
Y 
Y
 
1
4 
3
5
 
M
 
N
 
 
 
Y 
2 
C
 
Y-
9
9
 
Y-
2
7
4
 
N
 
Y 
N
 
3
 
N
 
N
 
1
5 
4
5
 
M
 
Y 
3 
C
 
Y 
4 
C
 
N
 
Y-
2
4
5
 
N
 
Y 
Y 
3
 
Y 
N
 
1
6 
5
6
 
M
 
Y 
7 
U
 
N
 
 
 
Y-
1
0
1
 
Y-
2
1
4
 
Y-
3
4 
N
 
Y 
3
 
Y 
Y
 
1
7 
6
8
 
F 
Y 
1
2 
U
 
Y 
1
1 
U
 
Y-
9
3
 
Y-
 1
8
8
 
Y-
4
4 
N
 
N
 
5
 
Y 
Y
 
1
8 
3
2
 
M
 
N
 
 
 
Y 
2 
C
 
N
 
Y-
1
7
2
 
Y-
3
6 
Y 
N
 
3
 
Y 
N
 
1
9 
4
5
 
M
 
y 
5 
C
 
Y 
5 
U
 
N
 
Y-
1
8
4
 
N
 
Y 
N
 
3
 
N
 
Y
 
2
0 
5
4
 
M
 
N
 
 
 
Y 
8 
U
 
N
 
Y-
1
9
9
 
Y-
3
5 
N
 
Y 
3
 
Y 
N
 
2
1 
4
6
 
F 
Y 
7 
U
 
Y 
5 
C
 
Y-
9
8
 
Y-
2
4
5
 
N
 
N
 
Y 
4
 
Y 
Y
 
2
2 
5
6
 
M
 
Y 
3 
C
 
Y 
3 
C
 
Y-
9
4
 
Y-
1
7
8
 
Y-
4
4 
N
 
N
 
4
 
Y 
Y
 
2
3 
3
8
 
F 
Y 
4 
C
 
N
 
 
 
Y=
1
1
9
 
Y-
2
9
8
 
N
 
N
 
N
 
3
 
Y 
Y
 
2
4 
4
4
 
F 
N
 
 
 
N
 
 
 
Y-
1
1
0
 
Y-
2
1
0
 
Y-
3
9 
N
 
N
 
3
 
Y 
Y
 
9
3
 
 
2
5 
5
4
 
F 
Y 
8 
U
 
Y 
3 
U
 
Y-
9
9
 
Y-
3
4
3
 
Y-
4
4 
N
 
N
 
5
 
Y 
Y
 
2
6 
6
5
 
F 
Y 
1
5 
U
 
Y 
1
5 
C
 
Y=
9
6
 
N
 
N
 
N
 
N
 
3
 
Y 
Y
 
2
7 
6
2
 
F 
Y 
5 
C
 
Y 
1
0 
C
 
Y-
1
1
0
 
N
 
N
 
N
 
N
 
3
 
Y 
N
 
2
8 
4
7
 
M
 
Y 
8 
U
 
Y 
5 
C
 
Y-
9
4
 
Y-
2
0
2
 
N
 
Y 
N
 
4
 
Y 
Y
 
2
9 
6
5
 
F 
Y 
2
1 
U
 
Y 
1
0 
C
 
Y-
1
0
1
 
Y-
1
8
9
 
N
 
N
 
N
 
4
 
Y 
Y
 
3
0 
4
0
 
M
 
N
 
 
 
Y 
5 
U
 
N
 
Y-
1
7
5
 
Y-
3
5 
N
 
N
 
3
 
N
 
N
 
3
1 
5
8
 
F 
Y 
1
1 
U
 
Y 
7 
C
 
Y-
9
1
 
Y=
1
7
0
 
N
 
N
 
N
 
4
 
Y 
Y
 
3
2 
5
1
 
M
 
Y 
7 
C
 
Y 
4 
C
 
N
 
Y-
1
9
8
 
N
 
N
 
Y 
3
 
Y 
N
 
3
3 
6
0
 
F 
Y 
1
6 
C
 
Y 
8 
U
 
Y-
1
0
1
 
N
 
N
 
N
 
N
 
3
 
Y 
Y
 
3
4 
6
3
 
F 
Y 
7 
C
 
Y 
1
4 
C
 
N
 
N
 
Y-
3
9 
N
 
N
 
3
 
Y 
N
 
3
5 
5
4
 
M
 
Y 
6 
U
 
Y 
6 
C
 
Y-
9
4
 
1
7
2
 
Y-
3
5 
Y 
N
 
5
 
Y 
Y
 
3
6 
6
5
 
F 
Y 
1
4 
U
 
Y 
6 
C
 
N
 
Y-
2
0
0
 
N
 
N
 
N
 
3
 
Y 
N
 
3
7 
7
9
 
M
 
Y 
2
4 
U
 
Y 
1
4 
C
 
Y-
1
1
0
 
Y-
2
4
1
 
N
 
Y 
N
 
4
 
Y 
Y
 
3
8 
8
0
 
M
 
Y-
 
2
2 
C
 
Y 
1
7 
C
 
Y-
9
8
 
N
 
Y-
3
5 
Y 
Y 
4
 
Y 
Y
 
3
9 
7
0
 
F 
Y 
1
6 
U
 
N
 
 
 
Y-
9
0
 
Y-
2
1
9
 
Y-
3
9 
N
 
N
 
4
 
Y 
Y
 
4
0 
3
6
 
F 
Y 
6 
U
 
N
 
 
 
Y-
9
5
 
Y-
2
5
0
 
Y-
3
5 
N
 
N
 
4
 
Y 
Y
 
4
1 
5
4
 
M
 
Y 
1
1 
C
 
Y 
1
2 
C
 
N
 
Y-
2
4
4
 
Y-
2
7 
Y 
Y 
4
 
Y 
N
 
4
2 
4
5
 
F 
N
 
 
 
Y 
9 
U
 
Y-
9
1
 
Y-
1
8
6
 
Y-
3
7 
N
 
N
 
4
 
N
 
Y
 
4
3 
8
2
 
M
 
Y 
2
3 
C
 
Y 
1
7 
C
 
N
 
Y-
1
8
7
 
N
 
Y 
Y 
3
 
Y 
Y
 
4
4 
4
9
 
F 
Y 
1
1 
U
 
Y 
6 
C
 
Y-
1
0
1
 
Y-
1
9
8
 
Y-
3
4 
N
 
N
 
5
 
Y 
Y
 
4
5 
7
4
 
F 
Y 
2
1 
C
 
Y 
1
6 
C
 
N
 
Y-
1
6
6
 
N
 
N
 
N
 
3
 
Y 
Y
 
4
6 
2
7
 
F 
N
 
 
 
N
 
 
 
Y-
1
1
8
 
Y-
1
7
7
 
Y-
3
9 
N
 
N
 
3
 
Y 
N
 
4
7 
3
5
 
M
 
Y 
5 
U
 
Y 
5 
C
 
N
 
Y-
1
6
7
 
Y-
3
2 
N
 
N
 
4
 
Y 
Y
 
4
8 
4
5
 
F 
N
 
 
 
Y 
1
0 
U
 
N
 
Y-
1
8
9
 
Y-
3
6 
N
 
N
 
3
 
Y 
N
 
4
9 
5
7
 
F 
Y 
9 
C
 
Y 
1
4 
U
 
Y-
9
5
 
Y-
1
6
8
 
N
 
N
 
N
 
4
 
Y 
Y
 
5
0 
6
9
 
F 
Y 
9 
C
 
N
 
 
 
Y-
1
0
4
 
Y-
2
9
8
 
Y-
3
5 
Y 
N
 
4
 
Y 
Y
 
 
 
94 
 
6. ABBREVIATIONS 
M- MALE 
F-FEMALE 
Y-YES 
N-NO 
C-CONTROLLED 
UC- UNCONTROLLED 
NV-NONVEG 
AB DIAMETER- ABDOMNIAL DIAMETER 
TGL- TRIGLYCERIDES 
HDL- HIGH DENSITY LIPOPROTEIN 
Hs CRP- high sensitive C reactive protein 
 
 
 
 
 
 
 
 
